Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Ramón Palmero et al.|The Lancet Oncology|2012Cited by 5.5k
P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLCBalázs Halmos, Enric Carcereny, E.H. Tan et al.|Journal of Thoracic Oncology|2018Cited by 1
Impact de la dose d’afatinib sur la tolérance et l’efficacité en vie réelle chez des patients avec CBNPC avancé EGFR mutéBalázs Halmos, Enric Carcereny, E.H. Tan et al.|Revue des Maladies Respiratoires|2018Cited by 0